Aisha Vadhariya1, Marc L Fleming2, Michael L Johnson3, E James Essien4, Omar Serna5, Tara Esse6, Jeannie Choi7, Susan H Boklage8, Susan M Abughosh9. 1. PhD Candidate, Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, TX. 2. Associate Professor, University of North Texas System College of Pharmacy, Houston. 3. Associate Professor, Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, TX. 4. Professor, Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, TX. 5. Clinical Operations Director at CareAllies, Houston. 6. Clinical Program Manager at CareAllies, Houston. 7. Former Director, Health Economics and Value Assessment, Sanofi. 8. Director, HEOR, Regeneron Pharmaceuticals, Tarrytown, NY. 9. Associate Professor, Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy.
Abstract
BACKGROUND: The benefits of statins in the prevention of primary and secondary atherosclerotic cardiovascular (CV) disease events have been well documented. Suboptimal adherence is a persistent problem associated with increased CV events and increased healthcare utilization. Proportion of days covered (PDC) is widely used to measure medication adherence, and provides a single value that does not adequately depict different adherence behavior patterns. Group-based trajectory modeling has been used to identify adherence patterns (or trajectories) over time. The identification of characteristics unique to each pattern can help in the early identification of patients who are likely to be poor adherents and can inform the development of interventions. OBJECTIVES: To identify distinct trajectories of statin adherence in patients enrolled in a Medicare Advantage plan and the sociodemographic and clinical predictors associated with each trajectory. METHODS: Patients were included in the study if they were continuously enrolled in a Medicare Advantage plan between 2013 and 2016 and had a statin prescription between January 2015 and June 2015. We observed each patient for 360 days and computed the monthly PDC. The monthly PDC was incorporated into a group-based trajectory model to provide distinct patterns of adherence. Using group-based trajectory modeling, the patients were categorized into groups based on their adherence patterns. Multinomial logistic regression was performed to identify the sociodemographic and clinical factors associated with each group. RESULTS: A total of 7850 patients were included in the analysis and were categorized into 4 distinct groups based on statin adherence-rapid discontinuation (7.8%), gradual decline (16.8%), gaps in adherence (17.2%), and high or nearly perfect adherence (58.2%). Significant predictors of being placed into one or more of the low-adherence trajectories compared with the high-adherence trajectory included sex, age, low-income subsidy, language, Charlson Comorbidity Index score, statin intensity, and 90-day refills. CONCLUSIONS: The predictors identified in this study provide valuable insight into patient characteristics that increase the risk for statin nonadherence, which has the potential to inform targeted interventions. Identifying patient trajectories can inform the future development of protocols to individualize appropriate interventions for these patients.
BACKGROUND: The benefits of statins in the prevention of primary and secondary atherosclerotic cardiovascular (CV) disease events have been well documented. Suboptimal adherence is a persistent problem associated with increased CV events and increased healthcare utilization. Proportion of days covered (PDC) is widely used to measure medication adherence, and provides a single value that does not adequately depict different adherence behavior patterns. Group-based trajectory modeling has been used to identify adherence patterns (or trajectories) over time. The identification of characteristics unique to each pattern can help in the early identification of patients who are likely to be poor adherents and can inform the development of interventions. OBJECTIVES: To identify distinct trajectories of statin adherence in patients enrolled in a Medicare Advantage plan and the sociodemographic and clinical predictors associated with each trajectory. METHODS: Patients were included in the study if they were continuously enrolled in a Medicare Advantage plan between 2013 and 2016 and had a statin prescription between January 2015 and June 2015. We observed each patient for 360 days and computed the monthly PDC. The monthly PDC was incorporated into a group-based trajectory model to provide distinct patterns of adherence. Using group-based trajectory modeling, the patients were categorized into groups based on their adherence patterns. Multinomial logistic regression was performed to identify the sociodemographic and clinical factors associated with each group. RESULTS: A total of 7850 patients were included in the analysis and were categorized into 4 distinct groups based on statin adherence-rapid discontinuation (7.8%), gradual decline (16.8%), gaps in adherence (17.2%), and high or nearly perfect adherence (58.2%). Significant predictors of being placed into one or more of the low-adherence trajectories compared with the high-adherence trajectory included sex, age, low-income subsidy, language, Charlson Comorbidity Index score, statin intensity, and 90-day refills. CONCLUSIONS: The predictors identified in this study provide valuable insight into patient characteristics that increase the risk for statin nonadherence, which has the potential to inform targeted interventions. Identifying patient trajectories can inform the future development of protocols to individualize appropriate interventions for these patients.
Authors: Eric J MacLaughlin; Cynthia L Raehl; Angela K Treadway; Teresa L Sterling; Dennis P Zoller; Chester A Bond Journal: Drugs Aging Date: 2005 Impact factor: 3.923
Authors: Michael D Murray; Daniel G Morrow; Michael Weiner; Daniel O Clark; Wanzhu Tu; Melissa M Deer; D Craig Brater; Morris Weinberger Journal: Am J Geriatr Pharmacother Date: 2004-03
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245
Authors: Joshua S Benner; Robert J Glynn; Helen Mogun; Peter J Neumann; Milton C Weinstein; Jerry Avorn Journal: JAMA Date: 2002 Jul 24-31 Impact factor: 56.272
Authors: Rajesh Balkrishnan; Rukmini Rajagopalan; Fabian T Camacho; Sally A Huston; Frederick T Murray; Roger T Anderson Journal: Clin Ther Date: 2003-11 Impact factor: 3.393
Authors: Chelsea E Hawley; Julie C Lauffenburger; Julie M Paik; Deborah J Wexler; Seoyoung C Kim; Elisabetta Patorno Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112
Authors: Zahra Majd; Anjana Mohan; Michael L Johnson; Ekere J Essien; Jamie C Barner; Omar Serna; Esteban Gallardo; Marc L Fleming; Nancy Ordonez; Marcia M Holstad; Susan M Abughosh Journal: Patient Prefer Adherence Date: 2022-10-04 Impact factor: 2.314
Authors: Jagadeswara R Earla; George J Hutton; J Douglas Thornton; Hua Chen; Michael L Johnson; Rajender R Aparasu Journal: Patient Prefer Adherence Date: 2020-11-04 Impact factor: 2.711
Authors: Rutugandha Paranjpe; Michael L Johnson; Ekere J Essien; Jamie C Barner; Omar Serna; Esteban Gallardo; Zahra Majd; Marc L Fleming; Nancy Ordonez; Marcia M Holstad; Susan M Abughosh Journal: Patient Prefer Adherence Date: 2020-10-13 Impact factor: 2.711